$0.95
3.95% yesterday
Nasdaq, Sep 24, 10:16 pm CET
ISIN
US0021201035
Symbol
ATYR

aTyr Pharma, Inc. Stock price

$0.95
-4.21 81.57% 1M
-2.75 74.30% 6M
-2.67 73.73% YTD
-0.79 45.34% 1Y
-1.88 66.40% 3Y
-2.90 75.30% 5Y
-211.71 99.55% 10Y
-208.35 99.55% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.04 3.95%
ISIN
US0021201035
Symbol
ATYR
Industry

Key metrics

Basic
Market capitalization
$93.2m
Enterprise Value
$14.0m
Net debt
positive
Cash
$80.4m
Shares outstanding
92.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 76.1
EV/Sales
- | 11.4
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
72.3%
Return on Equity
-91.4%
ROCE
-81.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $1.2m
EBITDA
$-68.1m | $-75.5m
EBIT
$-70.0m | $-75.2m
Net Income
$-66.6m | $-69.8m
Free Cash Flow
$-55.7m
Growth (TTM | estimate)
Revenue
-100.0% | 410.0%
EBITDA
-10.1% | -13.7%
EBIT
-12.0% | -10.7%
Net Income
-15.1% | -9.0%
Free Cash Flow
13.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -6,166.7%
EBIT
-
Net
- | -5,703.8%
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
35.9%
Employees
-
Rev per Employee
-
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
94%
Hold
6%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
25% 25%
-
- Research and Development Expense 54 54
8% 8%
-
-68 -68
10% 10%
-
- Depreciation and Amortization 1.96 1.96
176% 176%
-
EBIT (Operating Income) EBIT -70 -70
12% 12%
-
Net Profit -67 -67
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
PRNewsWire
2 days ago
SAN FRANCISCO , Sept. 23, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal.
Neutral
GlobeNewsWire
3 days ago
SAN FRANCISCO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal.
Neutral
PRNewsWire
6 days ago
SAN FRANCISCO , Sept. 19, 2025 /PRNewswire/ -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease ("ILD"), did not meet its main goal.
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today